- Policy
- "Long-waited patent expiration"…17 Xeljanz generics
- by Jung, Heung-Jun Oct 24, 2025 06:16am
- Pfizer Korea's rheumatoid arthritis treatment 'Xeljanz (tofacitinib)' is set to be included on the National Health Insurance reimbursement list next month, joining the market competition. According to the industry on October 23, 12 pharmaceutical companies and 17 items will receive reimbursement coverage as of November 23, the next day af
- Company
- ‘Reimb targeted therapies for Stage IV gastric cancer'
- by Son, Hyung Min Oct 24, 2025 06:15am
- A targeted therapy option for gastric cancer that demonstrated exceptional survival extension benefits in Asian patients is on the verge of being listed for insurance reimbursement in Korea. If reimbursed, the medical community expects the improved access to the new drug will contribute to improving the persistently low survival rates among meta
- Policy
- NA presses for reimb of Vyloy, Imjudo, Yescarta
- by Jung, Heung-Jun Oct 24, 2025 06:14am
- The National Assembly directly mentioned drugs for severe diseases like Vyloy, Imjudo, Yescarta, and pressed the Ministry of Health and Welfare to promptly grant the drug’s reimbursement expansions. The Ministry responded, “We will expedite the process,” which is expected to act as a tailwind for HIRA's reimbursement decision discussio
- Company
- Metalyse is approved for acute ischemic stroke in KOR
- by Son, Hyung Min Oct 24, 2025 06:14am
- Boehringer Ingelheim Korea (General Manager: Anna-Maria Boie) announced on the 23rd that the Ministry of Food and Drug Safety approved Metalyse (tenecteplase) as a treatment for acute ischemic stroke in adults on October 2. The approval marks the first new option introduced for acute ischemic stroke in roughly two decades, following Actilyse
- Company
- "Lirafugratinib demonstrated to selectively inhibit FGFR2"
- by Hwang, byoung woo Oct 24, 2025 06:13am
- Clinical data for HLB’s FGFR2-targeted anti-cancer drug, 'lirafugratinib,' were presented at the ESMO Congress 2025 (European Society for Medical Oncology). Professor Richard Kim of the Moffitt Cancer Center in the U.S., who participated as a clinician in the study, discussed lirafugratinib’s differentiation, clinical significance, and pote
- Company
- BTN1A1 effective in PD-L1–negative, resistant tumors
- by Hwang, byoung woo Oct 23, 2025 06:12am
- STCube is venturing into one of immuno-oncology’s uncharted territories. The company has been exploring therapeutic responses of its first-in-class BTN1A1-targeting drug candidate, Nelmastobart, in patients with PD-L1&8211;negative or PD-1-resistant tumors, marking the first step toward realizing precision immunotherapy. At the European
- Policy
- "Will establish preferential pricing for drug R&D"
- by Lee, Jeong-Hwan Oct 23, 2025 06:12am
- Minister of Health and Welfare Jeong Eun Kyeong is drawing attention after stating, "It is necessary to reform the pharmaceutical company compensation system through a drug pricing system linked to R&D investment. The Ministry will prepare measures to improve the drug pricing system." Minister Jeong also promised, "The Ministry will prepa
- Company
- "AI pathology analysis changes trt paradigm…Lunit presents"
- by Hwang, byoung woo Oct 23, 2025 06:11am
- At the European Society for Medical Oncology conference (ESMO Congress 2025), Lunit presented new clinical evidence for its Artificial Intelligence (AI) pathology analysis. The results are particularly significant as Lunit demonstrated that AI can distinguish treatment response in a subset of proficient mismatch repair (pMMR) colorectal cance
- Policy
- ‘Expanding dual pricing under review to mitigate risks’
- by Jung, Heung-Jun Oct 23, 2025 06:11am
- The Ministry of Health and Welfare has expressed its commitment to actively review plans to expand the dual drug pricing system to resolve risks associated with the introduction of innovative new drugs. The MOHW expressed consensus on the need for the expansion as a countermeasure to the Most-Favored-Nation (MFN) drug pricing system intro
- Policy
- MOHW to institutionalize a fast-track listing system
- by Jung, Heung-Jun Oct 23, 2025 06:10am
- The Ministry of Health and Welfare (MOHW) has announced plans to institutionalize a fast-track reimbursement system based on the outcomes of the ongoing “approval&8211;evaluation&8211;negotiation” pilot program, aimed at accelerating patient access to innovative new drugs. It also stated its intention to expedite the reimbursement dec
